
KAPA Stock Forecast & Price Target
KAPA Analyst Ratings
Bulls say
Kairos Pharma Ltd demonstrates a strong potential for growth, highlighted by a median progression-free survival of 13.7 months for the ENV-105 plus apalutamide regimen, indicating a competitive edge over traditional therapies. The company maintains a solid financial foundation with controlled cash burn, supported by recent capital raises and grants, which provide a sustainable runway for its ongoing clinical trials and development programs. Furthermore, the positive interim results from the Phase 2 trial of ENV-105 in advanced prostate cancer emphasize the effectiveness of its oncology pipeline and may attract strategic partnerships as the company progresses towards later-stage development.
Bears say
Kairos Pharma Ltd, a clinical-stage biopharmaceutical company, reported no product revenues for the quarter ended June 30, 2025, indicating a lack of commercial viability for its therapeutics at this stage. The company incurred a net loss of approximately $1.4 million for the three-month period and $2.7 million for the first half of 2025, which raises concerns about its financial sustainability. Despite some promising biological activity demonstrated in its treatments, the absence of revenue and ongoing losses highlight significant risks for investors looking at future growth potential.
This aggregate rating is based on analysts' research of Kairos Pharma Ltd and is not a guaranteed prediction by Public.com or investment advice.
KAPA Analyst Forecast & Price Prediction
Start investing in KAPA
Order type
Buy in
Order amount
Est. shares
0 shares